Value of two-phase [68Ga]Ga-PSMA PET/CT imaging in comparison with optimized delayed imaging in detecting locoregional prostatic metastases

Document Type : Original Article

Authors

Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Introduction: [68Ga]Ga-PSMA PET/CT has gained acceptance for localizing local and distant metastases; However, urinary activity remains a confounding factor in interpreting local metastases. The aim of this study was to evaluate the diagnostic value of two-phase protocol (i.e., early and regular imaging, TPP) in comparison with delayed optimized protocol (i.e., combined regular and delayed post hydration and diuresis images, DOP) to detect locoregional prostatic metastases.
Methods: Forty-one prostate cancer patients referred for staging (n = 12) or the evaluation of rise in PSA level in prostate cancer (n = 29) were prospectively assessed. In this study, each patient received an early 5-10 min image from pelvic region for two bed position, regular (RP) (60 min) and finally delayed static images. The scan findings were characterized as positive, negative or equivocal. The diagnostic significance of TPP was compared with DOP for prostatic, periprostatic, locoregional lymph nodes and pelvic bone involvement.
Results: The diagnostic agreement between DOP and TPP for prostate/prostate bed lesions was comparable with the agreement of DOP and RP (Kappa: 0.78, p < 0.001) vs. (Kappa: 0.8, p value < 0.001). TPP in comparison with RP, had superior sensitivity for prostate/prostate bed lesions (95% vs. 80%). The sensitivity for lymph node metastases, extraprostatic extension and osteometastases was identical between the two protocols.
Conclusion: TPP has the potential to replace DOP for the evaluation of prostate/prostate bed lesions; however, there remains instances where delayed imaging is helpful in characterizing the anatomic abnormality especially in the lymph node region.

Keywords

Main Subjects

References

  1. Fallahi B, Khademi N, Karamzade-Ziarati N, Fard-Esfahani A, Emami-Ardekani A, Farzanefar S, Eftekhari M, Beiki D. 99mTc-PSMA SPECT/CT versus 68Ga-PSMA PET/CT in the evaluation of metastatic prostate cancer. Clin Nucl Med. 2021 Feb 1;46(2):e68-e74.
  2. Sahebkari A, Soltani S, Ghorbani H, Aryana K, Kabiri M, Sadri K, Mottaghi M, Aghaee A. Comparing the diagnostic efficacy of [99mTc]Tc-HYNIC-PSMA-11 SPECT/CT scanning after 75 minutes and 4 hours of radiotracer injection in men with prostate cancer. Iran J Nucl Med. 2024;32(1):9-15.
  3. Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, Christidis D, Bolton D, Hofman MS, Lawrentschuk N, Murphy DG. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 2020 Apr;77(4):403-17. 
  4. Jadvar H, Calais J, Fanti S, Feng F, Greene KL, Gulley JL, Hofman M, Koontz BF, Lin DW, Morris MJ, Rowe SP, Royce TJ, Salami S, Savir-Baruch B, Srinivas S, Hope TA. Appropriate use criteria for prostate-specific membrane antigen pet imaging. J Nucl Med. 2022 Jan;63(1):59-68.
  5. Hope TA, Jadvar H. Updates to appropriate use criteria for PSMA PET. J Nucl Med. 2022 May;63(5):14N. 
  6. Uprimny C, Bayerschmidt S, Kroiss AS, Fritz J, Nilica B, Svirydenka H, Decristoforo C, von Guggenberg E, Horninger W, Virgolini IJ. Early injection of furosemide increases detection rate of local recurrence in prostate cancer patients with biochemical recurrence referred for 68Ga-PSMA-11 PET/CT. J Nucl Med. 2021 Nov;62(11):1550-7.
  7. Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, Cho SY, Fanti S, Giesel FL, Goffin K, Haberkorn U, Jacene H, Koo PJ, Kopka K, Krause BJ, Lindenberg L, Marcus C, Mottaghy FM, Oprea-Lager DE, Osborne JR, Piert M, Rowe SP, Schöder H, Wan S, Wester HJ, Hope TA, Herrmann K. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1466-86. 
  8. Koyama K, Okamura T, Kawabe J, Ozawa N, Torii K, Umesaki N, Miyama M, Ochi H, Yamada R. Evaluation of 18F-FDG PET with bladder irrigation in patients with uterine and ovarian tumors. J Nucl Med. 2003 Mar;44(3):353-8.
  9. Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):471-95. 
  10. Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, Kesch C, Tolstov Y, Singer S, Grabe N, Duensing S, Schäfer M, Neels OC, Mier W, Haberkorn U, Kopka K, Kratochwil C. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):678-88. 
  11. Alberts I, Mingels C, Zacho HD, Lanz S, Schöder H, Rominger A, Zwahlen M, Afshar-Oromieh A. Comparing the clinical performance and cost efficacy of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 in the diagnosis of recurrent prostate cancer: a Markov chain decision analysis. Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4252-61.
  12. Perveen G, Arora G, Damle NA, Prabhu M, Arora S, Tripathi M, Bal C, Kumar P, Kumar R, Singh P, Das CJ, Passah A. Can early dynamic positron emission tomography/computed tomography obviate the need for postdiuresis image in 68Ga-PSMA-HBED-CC scan for evaluation of prostate adenocarcinoma? Indian J Nucl Med. 2018 Jul-Sep;33(3):202-8. 
  13. Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, Giesel F, Haberkorn U, Hope TA, Kopka K, Krause BJ, Mottaghy FM, Schöder H, Sunderland J, Wan S, Wester HJ, Fanti S, Herrmann K. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1014-24.
  14. Harsini S, Fallahi B, Ziarati NK, Razi A, Amini E, Emami-Ardekani A, Fard-Esfahani A, Parizi MK, Farzanehfar S, Beiki D. A prospective study on [68Ga]-PSMA PET/CT imaging in newly diagnosed intermediate-and high-risk prostate cancer. Asia Oceania J Nucl Med Biol. 2021;9(2):101.
  15. Uprimny C, Kroiss AS, Fritz J, Decristoforo C, Kendler D, von Guggenberg E, Nilica B, Maffey-Steffan J, di Santo G, Bektic J, Horninger W, Virgolini IJ. Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence. Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1647-55.
  16. Mao J, Gao M, Cui B, Zhang Y, Wang X, Liang S, Zuo C, Chen P, Dong A. Super early scan of PSMA PET/CT in evaluating primary and metastatic lesions of prostate cancer. Molecules. 2022 Jul 21;27(14):4661.
  17. Kabasakal L, Demirci E, Ocak M, Akyel R, Nematyazar J, Aygun A, Halac M, Talat Z, Araman A. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl Med Commun. 2015 Jun;36(6):582-7.
  18. Barakat A, Yacoub B, Homsi ME, Saad Aldine A, El Hajj A, Haidar MB. Role of early PET/CT imaging with 68Ga-PSMA in staging and restaging of prostate cancer. Sci Rep. 2020 Feb 17;10(1):2705.
  19. Bayerschmidt S, Uprimny C, Kroiss AS, Fritz J, Nilica B, Svirydenka H, Decristoforo C, von Guggenberg E, Horninger W, Virgolini IJ. Comparison of early imaging and imaging 60 min post-injection after forced diuresis with furosemide in the assessment of local recurrence in prostate cancer patients with biochemical recurrence referred for 68Ga-PSMA-11 PET/CT. Diagnostics. 2021 Jun 30;11(7):1191.
  20. Afshar-Oromieh A, Sattler LP, Mier W, Hadaschik BA, Debus J, Holland-Letz T, Kopka K, Haberkorn U. The clinical impact of additional late PET/CT imaging with 68Ga-PSMA-11 (HBED-CC) in the diagnosis of prostate cancer. J Nucl Med. 2017 May 1;58(5):750-5.
  21. Sahlmann CO, Meller B, Bouter C, Ritter CO, Ströbel P, Lotz J, Trojan L, Meller J, Hijazi S. Biphasic ⁶⁸Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma. Eur J Nucl Med Mol Imaging. 2016 May;43(5):898-905.
  22. Beheshti M, Manafi-Farid R, Geinitz H, Vali R, Loidl W, Mottaghy FM, Langsteger W. Multiphasic 68Ga-PSMA PET/CT in the detection of early recurrence in prostate cancer patients with a PSA level of less than 1 ng/mL: a prospective study of 135 patients. J Nucl Med. 2020 Oct 1;61(10):1484-90.
  23. Fennessy N, Lee J, Shin J, Ho B, Ali SA, Paschkewitz R, Emmett L. Frusemide aids diagnostic interpretation of 68 Ga-PSMA positron emission tomography/CT in men with prostate cancer. J Med Imaging Radiat Oncol. 2017 Dec;61(6):739-44.

Files

Share

How to cite

Statistics